Form 4: REGENXBIO Director George Migausky Reports Stock and Option Transactions

Director George Migausky reports acquisition of common stock and stock options in REGENXBIO Inc.

Summary

• On May 31, 2024, George Migausky, a director of REGENXBIO Inc., acquired 4,790 shares of common stock related to a restricted stock unit award.
• These shares were acquired at a price of $0.00.
• 100% of the shares subject to the RSU will vest on May 1, 2025, contingent upon continuous service to the Issuer.
• Migausky also acquired 24,454 stock options with an exercise price of $14.35 on the same date.
• These options will vest in 12 equal monthly installments following May 31, 2024, subject to continuous service.
• Following these transactions, Migausky beneficially owns 11,286 shares of common stock and 24,454 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine transactions. The acquisition of shares and options by a director is generally viewed positively, but it's a standard occurrence.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the director's continuous service to the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates